natgillin/translations-raw huggingface dataset:
Wind system (1) according to claim 1, characterised in that each of said modules (5) is equipped with permanent magnets, said permanent magnets inducing currents in said electromagnets with which said rail (6) is equipped so that said currents partly generate a magnetic field that is opposed to the inducing one making said module (5) levitate, said permanent magnets being preferably helped by superconductor solenoids. 
Vjetreni sustav (1) prema zahtjevu 1, naznačen time da je svaki od spomenutih modula (5) opremljen permanentnim magnetima, pri čemu spomenuti permanentni magneti induciraju struju u spomenute elektromagnete kojima je opremljena spomenuta tračnica (6) tako da ta struja djelomično pokreće magnetsko polje koje se suprotstavlja onome koje proizvodi struju, zbog čega spomenuti modul (5) levitira.
a re-condenser vessel (15) feeded by liquefied natural gascomprising: 
posudu za rekondenzaciju (15) koja se puni ukapljenim prirodnim plinom i sadrži:
• a liquefied natural gas bottom inlet (23) arranged at the lower accumulation zone (12) and through which the surplus of liquefied natural gas up to some specific send-out rate is introduced; 
• Donji ulaz za ukapljeni prirodni plin (23) smješten u donjoj akumulacijskoj zoni (12) kroz koji se specifičnom stopom ispuštanja uvodi višak ukapljenog prirodnog plina;
a liquefied natural gas flow controller (1) for controlling the flow rate of sub-cooled liquefied natural gas introduced into the re-condenser vessel (15) through the liquefied natural gas top inlet (22) to maintain the desired pressure inside the re-condenser vessel (15); 
regulator protoka ukapljenog prirodnog plina (1) za kontrolu stope protoka pothlađenog ukapljenog prirodnog plina koji se uvodi u rekondenzacijsku posudu (15) kroz gornji ulaz za ukapljeni prirodni plin (22) kako bi se održao željeni pritisak unutar rekondenzacijske posude (15);
a level controller (6) which comprises at least one level control valve (3) for controlling the level of the liquefied natural gas in the lower accumulation zone (12); 
regulator protoka (6) koji sadrži barem jedan ventil za kontrolu razine (3) za kontrolu razine ukapljenog prirodnog plina u donjoj akumulacijskoj zoni (12);
characterized in that the system further comprises: 
naznačen time da sustav nadalje sadrži:
a liquefied natural gas controlled bypass line (24) for bypassing the re-condenser vessel (15) with the remaining of the send-out flow of liquefied natural gas taken from the discharge of low-pressure pumps (32); 
kontrolirani premosni vod (24) za ukapljeni prirodni plin za premošćivanje rekondenzacijske posude (15) ostatkom ispuštenog toka ukapljenog prirodnog plina dobivenog iz ispusta niskotlačnih crpki (32);
and in that the boil-off gas inlet (14) is arranged at the top section of the re-condenser vessel (15). 
te da je ulaz isparenog plina (14) smješten na gornjem dijelu rekondenzacijske posude (15).
Boil-off gas re-condenser system according to claim 1, further comprising a padding gas entry (30) from vaporisers send-out upstream a metering station for maintaining the re-condenser vessel (15) operating pressure at a minimum pressure set point and a controlled vent connection (33) to prevent high pressure in the re-condenser vessel (15). 
Sustav rekondenzatora isparenog plina sukladno Zahtjevu 1, nadalje sadrži ulaz za punjenje plinom (30) od vaporizatora usmjerenih uzlazno uz postaju za mjerenje za održavanje rekondenzacijske posude (15) držeći pritisak na točci najnižeg pritiska i kontroliranog otvora za povezivanje (33) kako bi se spriječilo visoki pritisak u rekondenzacijskoj posudi (15).
Boil-off gas re-condenser system according to claim 2 or 3, further comprising a pressure controller loop (17) for padding gas and a pressure controller loop (19) for the pressure release. 
Sustav rekondenzatora isparenog plina sukladno Zahtjevu 2 i 3, nadalje sadrži petlju za kontrolu pritiska (17) za punjenje plinom u petlju za kontrolu pritiska (19) za otpuštanje pritiska.
A combination of at least one sigma ligand and at least one chemotherapeutic drug for simultaneous, separate or sequential administration, wherein the sigma ligand has the general formula (I): wherein 
Kombinacija barem jednog sigma liganda i barem jednog kemoterapijskog lijeka za istovremeno, odvojeno ili uzastopno davanje, naznačena time da sigma ligand ima opću formulu (I): [image] pri čemu
and the chemotherapeutic drug is selected from the group formed by taxanes, vinca alkaloids, drugs derived from platinum and thalidomide. 
i kemoterapijski lijek je odabran iz skupine koju čine taksani, vinka alkaloidi, lijekovi dobiveni od platine i talidomida.
ii) substituted or unsubstituted C1-C10 linear, branched, or cyclic alkyl; 
ii) supstituiranog ili nesupstituiranog C1-C10 nerazgranatog, razgranatog ili prstenastog alkila;
iii) substituted or unsubstituted C2-C10 linear, branched, or cyclic alkenyl; 
iii) supstituiranog ili nesupstituiranog C2-C10 nerazgranatog, razgranatog ili prstenastog alkenila;
iv) substituted or unsubstituted C2-C10 linear or branched alkynyl; 
iv) supstituiranog ili nesupstituiranog C2-C10 nerazgranatog ili razgranatog alkinila;
A combination according to 1 wherein the pharmaceutically acceptable salt of a compound of formula (I) is the sodium salt. 
Kombinacija u skladu s patentnim zahtjevom 1, naznačena time što je farmaceutski prihvatljiva sol spoja formule (I) natrijeva sol.
A compound represented by the general formula (1) or a pharmaceutically acceptable salt thereof: (wherein R1 and R2 are each independently a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulfamoyl group, a C1 to C6 alkyl group, a C1 to C6 alkoxy group, a C1 to C6 alkylsulfanyl group, a C1 to C6 alkylsulfinyl group, a C1 to C6 alkylsulfonyl group, or a C1 to C6 alkoxy-C1 to C6 alkylsulfonyl group, and A is a substituted or unsubstituted heteroaryl group). 
Spoj prikazan općom formulom (1) ili njegova farmaceutski prihvatljiva sol: [image] naznačen time da su R1 i R2 svaki neovisno vodikov atom, atom halogena, amino skupina, hidroksil skupina, hidroksilamino skupina, nitro skupina, cijano skupina, sulfamoil skupina, C1 do C6 alkil skupina, C1 do C6 alkoksi skupina, C1 do C6 alkilsulfanil skupina, C1 do C6 alkilsulfinil skupina, C1 do C6 alkilsulfonil skupina, C1 do C6 alkoksi-C1 do C6alkilsulfonil skupina i A je supstituirana ili nesupstituirana heteroaril skupina.
p is 0, 1, 2, 3, 4, 5, or 6; and q is 0, 1, 2, 3, 4, 5 or 6; and a pharmaceutically acceptable carrier; wherein said composition is suitable for oral administration and for providing sustained release of said compound or said salt. 
p je 0, 1, 2, 3, 4, 5 ili 6; i q je 0, 1, 2, 3, 4, 5 ili 6. i farmaceutski prihvatljiv nosač; pri čemu je navedeni sastav pogodan za oralnu primjenu i za osiguravanje produženog oslobađanja navedenog spoja ili navedene soli.
or a pharmaceutically acceptable salt thereof. The pharmaceutical composition according to claim 1, wherein said compound is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; or a pharmaceutically acceptable salt thereof. 
Farmaceutski sastav koji sadrži spoj koji je 3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitril; ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač; pri čemu je navedeni sastav pogodan za oralnu primjenu i za osiguravanje produženog oslobađanja navedenog spoja ili navedene soli.
A method for detecting a propensity for developing inflammatory bowel disease (IBD) in a patient, the method comprising: detecting the presence of at least one single nucleotide polymorphism on chromosome 20q13 in a target polynucleotide wherein if said at least one single nucleotide polymorphism is present, said patient has an increased risk for developing IBD, wherein said at least one single nucleotide polymorphism is a T at rs2315008 or an A at rs4809330 close to the TNFRSF6B gene. 
Postupak otkrivanja vjerojatnosti razvoja upalne bolesti crijeva (IBD) kod pacijenta, naznačen time, da postupak obuhvaća otkrivanje prisutnosti najmanje jednog zasebnog nukleotida polimorfizma na kromosomu 20q13 u ciljanom polinukleotidu, tako da kada je prisutan navedeni najmanje jedan zaseban nukleotid polimorfizma, tada spomenuti pacijent ima povećani rizik za razvoj IBD, pri čemu navedeni najmanje jedan zaseban nukleotid polimorfizma je T na rs2315008 ili je A na rs4809330 u blizini TNFRSF6B gena.
A method according to claim 1 further comprising detecting the presence of at least one single nucleotide polymorphism in a target polynucleotide wherein said at least one single nucleotide polymorphism is set forth in a Table selected from the group consisting of Table 6A, Table 6B, Table 13, Table 14, Table 15, Table 16, Table 17, Table 18, and Table 19. 
Postupak prema zahtjevu 1, naznačen time, da nadalje obuhvaća otkrivanje prisutnosti najmanje jednog zasebnog nukleotida polimorfizma u ciljanom polinukleotidu, pri čemu je navedeni najmanje jedan zaseban nukleotid polimorfizma iznesen u Tablici odabranoj iz skupine koju čine Tablica 6A, Tablica 6B, Tablica 13, Tablica 14, Tablica 15, Tablica 16, Tablica 17, Tablica 18 i Tablica 19.
detecting the presence of a single nucleotide polymorphism on chromosome 21q22 wherein if said single nucleotide polymorphism is present, said patient has an increased risk for developing IBD, wherein said single nucleotide polymorphism is an A at rs28336878 close to the PSMG1 gene. 
otkrivanje prisutnosti zasebnog nukleotida polimorfizma na kromosomu 21q22, tako da kada je prisutan navedeni zaseban nukleotid polimorfizma, tada spomenuti pacijent ima povećani rizik za razvoj IBD, pri čemu navedeni zaseban nukleotid polimorfizma je A na rs28336878 u blizini PSMG1 gena.
Use of an isolated nucleic acid in a method of detecting the propensity to develop IBD, said nucleic acid comprising a single nucleotide polymorphism associated with an increased risk of developing IBD selected from the group consisting of a T at rs2315008 or an A at RS4809330 in the TNFRSF6B gene and an A at rs2836878 in the PSMG1 gene. 
Uporaba izolirane nukleinske kiseline, naznačena time, da služi u postupku otkrivanja vjerojatnosti za razvoj IBD, pri čemu navedena nukleinska kiselina sadrži zaseban nukleotid polimorfizma, povezan s povećanim rizikom razvoja IBD, koji je odabran iz skupine koju čine T na rs2315008 ili A na rs4809330 u TNFRSF6B genu i A na rs2836878 u PSMG1 genu.
providing previously obtained colonic biopsy samples expressing a single nucleotide polymorphism selected from the group consisting of a T at rs2315008 or an A at RS4809330 in the TNFRSF6B gene and an A at rs2836878 in the PSMG1 gene; 
pribavljanje prethodno dobivenih uzoraka crijevne biopsije, koji izražavaju zaseban nukleotid polimorfizma odabran iz skupine koju čine T na rs2315008 ili A na rs4809330 u TNFRSF6B genu i A na rs2836878 u PSMG1 genu;
contacting the cells of steps a) and b) with a test agent and 
stavljanje u doticaj stanica iz koraka a) i b) s ispitnim sredstvom; i
analyzing whether said agent alters an aberrant physiological process associated with IBD in samples of step a) relative to those of step b), thereby identifying agents which modulate inflammatory bowel disease. 
analiziranje koliko spomenuta tvar mijenja neprirodni fiziološki process povezan s IBD u uzorcima iz koraka a) u odnosu na one iz koraka b), čime se identificiraju tvari koje moduliraju upalnu bolest crijeva.
a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; 
inhibitor nukleozidne reverzne transkriptaze i/ili inhibitor nukleotidne reverzne transkriptaze; pri čemu su TMC278 i inhibitor nukleotidne reverzne transkriptaze inhibitor i inhibitor nukleozidne reverzne transkriptaze terapeutski učinkoviti inhibitori HIV-a u dozi koja se može davati jednom dnevno;
for use in the treatment of HIV infection wherein the combination is administered once daily. 
za uporabu kod liječenja HIV infekcije naznačena time da se kombinacija daje jednom dnevno.
a nucleoside reverse transcriptase inhibitor, and 
inhibitor nukleozidne reverzne transkriptaze, i
a second nucleoside reverse transcriptase inhibitor other than the nucleoside reverse transcriptase inhibitor of (ii); wherein TMC278 and the nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily. 
drugi inhibitor nukleozidne reverzne transkriptaze koji je različit od inhibitora nukleozidne reverzne transkriptaze iz (ii); pri čemu su TMC278 i inhibitori nukleozidne reverzne transkriptaze terapeutski učinkoviti inhibitori HIV-a u dozi koja se može davati jednom dnevno.
TMC278 or its stereoisomeric form or pharmaceutically acceptable salt, 
TMC278 ili njegov stereoizomerni oblik ili farmaceutski prihvatljivu sol,
Use of a pharmaceutical formulation as claimed in claim 31 or 32 for the manufacture of a medicament for the treatment of HIV infection wherein the formulation is administered once daily. 
Uporaba farmaceutske formulacije prema zahtjevu 31 ili 32, naznačena time da je za proizvodnju lijeka za liječenje HIV infekcije pri čemu se formulacija daje jednom dnevno.
An isolated monoclonal antibody, or antigen binding fragment as claimed in claim 1 comprising a heavy chain variable region having at least 80%, 90%, 95%, 97%, 98% or 99% sequence identity to an amino acid sequence of SEQ ID NO: 7; and a light chain variable region having at least 80%, 90%, 95%, 97%, 98% or 99% sequence identity to an amino acid sequence of SEQ ID NO: 8. 
Izolirano monoklonalno protutijelo ili njegov fragment koji se veže na antigen, prema zahtjevu 1, naznačen/o time, da obuhvaća varijabilno područje jakog lanca, koje ima najmanje 80%, 90%, 95%, 97%, 98% ili 99% identiteta sekvence prema aminokiselinskoj sekvenci od SEQ ID NO:7; i varijabilno područje slabog lanca, koje ima najmanje 80%, 90%, 95%, 97%, 98% ili 99% identiteta sekvence prema aminokiselinskoj sekvenci od SEQ ID NO:8.
An isolated monoclonal antibody, or antigen binding fragment as claimed in any previous claim comprising a heavy chain having at least 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 9; and a light chain having at least 95%, 97%, 98% or 99% sequence identity to SEQ ID NO: 10. 
Izolirano monoklonalno protutijelo ili njegov fragment koji se veže na antigen, prema bilo kojem od prethodnih zahtjeva, naznačen/o time, da obuhvaća jaki lanac koji ima najmanje 95%, 96%, 97%, 98% ili 99% identiteta sekvence prema SEQ ID NO:9; i slabi lanac koji ima najmanje 95%, 96%, 97%, 98% ili 99% identiteta sekvence prema SEQ ID NO:10.
An isolated monoclonal antibody, or antigen binding fragment as claimed in claim 4 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 9; and a light chain having the amino acid sequence of SEQ ID NO: 10. 
Izolirano monoklonalno protutijelo ili njegov fragment koji se veže na antigen, prema zahtjevu 4, naznačen/o time, da obuhvaća jaki lanac koji ima aminokiselinsku sekvencu od SEQ ID NO:9; i slabi lanac koji ima aminokiselinsku sekvencu od SEQ ID NO:10.
The antibody as claimed in any one of claims 1 to 5 which inhibits the alternative complement pathway with an IC50 of 20-200 pM as measured by in vitro hemolytic assay when using human C5 depleted serum that is reconstituted with 100 pM human C5. 
Protutijelo prema bilo kojem od zahtjeva 1 do 5, naznačeno time, da posjeduje alternativni komplementni put s IC50 od 20-200 pM, kao što se mjeri pomoću hemolitičkog testiranja in vitro, uporabom iscrpljenog seruma humanog C5, koji se rekonstituira s 100 pM humanog C5.
A pharmaceutical composition comprising the antibody or antigen binding fragment as claimed in any previous claim and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća protutijelo ili njegov fragment koji se veže na antigen, prema bilo kojem od prethodnih zahtjeva i farmaceutski prihvatljiv nosač.
Th nucleic acid as claimed in claim 10, comprising a nucleotide sequence encoding a polypeptide comprising a heavy chain variable region having at least 95% sequence identity to SEQ ID NO: 7, or a light chain variable region having at least 95% sequence identity to SEQ ID NO: 8. 
Nukleinska kiselina prema zahtjevu 10, naznačena time, da obuhvaća nukleotidnu sekvencu koja kodira polipeptid koji ima vrijabilno područje jakog lanca s najmanje 95% identiteta sekvence prema SEQ ID NO:7, ili varijabilno područje slabog lanca s najmanje 95% identiteta sekvence prema SEQ ID NO:8.
The antibody or antigen binding fragment as claimed in any one of claims 1 to 8, or the pharmaceutical composition as claimed in claim 9 for use in treating age related macular degeneration, asthma, arthritis, autoimmune heart disease, multiple sclerosis, inflammatory bowel disease, ischemia-reperfusion injuries, Barraquer-Simons Syndrome,, systemic lupus, lupus erythematosus, psoriasis, multiple sclerosis,, Alzheimer's disease, glomerulonephritis, paroxysmal nocturnal hemoglobinuria (PNH), or MPGN II. 
Protutijelo ili njegov fragment koji se veže na antigen prema bilo kojem od zahtjeva 1 do 8, ili farmaceutski sastav prema zahtjevu 9, naznačen/o time, da se upotrebljava u liječenju sljedećih stanja: makularna degeneracija povezana sa starošću, astma, artritis, autoimuna srčana bolest, multipla skleroza, upalna bolest crijeva, ishemijske-reperfuzijske ozljede, sindrom Barraquer-Simons, sistemski lupus, lupus eritematoza, psorijaza, multipla skleroza, Alzheimerova bolest, glomerulonefritis, paroksizmalna nokturalna hemoglobinurija (PNH) ili MPGN II.
The antibody or antigen binding fragment as claimed in any one of claims 1 to 8, or the pharmaceutical composition as claimed in claim 9 for use in a method of reducing the dysfunction of the immune and hemostatic systems associated with extracorporeal circulation by administering the antibody or antigen binding fragment thereof or the pharmaceutical composition to a subject in need thereof. 
Protutijelo ili njegov fragment koji se veže na antigen prema bilo kojem od zahtjeva 1 do 8, ili farmaceutski sastav prema zahtjevu 9, naznačen/o time, da se upotrebljava u postupku smanjivanja disfunkcije imunološkog i hemostatskog sustava, povezane s izvantjelesnom cirkulacijom, putem davanja pacijentu kojemu je to potrebno, protutijela ili njegovog fragmenta koji se veže na antigen, ili farmaceutskog sastava.
ZisH. The compound of claim 1, selected from: 
Farmaceutski sastav prema zahtjevu 1, pri čemu je navedeni spoj izabran od:
a bore or passageway (18) extending through the plastic body portion (12) and having a first opening proximate the first end (16) and a second opening at the second end (14); 
provrta ili prolaza (18) koji prolazi kroz plastični dio tijela (12) i ima prednji otvor koji je u blizini prednjeg kraja (16) i stražnji otvor na stražnjem kraju (14);
The injection nozzle according to at least one of claims 1 to 6, wherein the finger or tongue (28) is constructed 
Mlaznica za injektiranje prema barem jednom od zahtjeva 1 do 6, naznačena time da je nastavak ili jezičac (28) konstruiran
of the same material as the plastic body portion (12) or 
od istog materijala kao plastični dio tijela (12) ili
The injection nozzle according to at least one of claims 1 to 7, wherein the housing or sheath (30) is a metallic housing or metallic sheath. 
Mlaznica za injektiranje prema barem jednom od zahtjeva 1 do 7, naznačena time da kućište ili omotač (30) je metalno kućište ili metalni omotač.
The injection nozzle according to claim 4 or 5, and in particular to at least one of claims 2 or 3 or 6 to 8, wherein the housing or sheath (30), in particular the sidewall, comprises a facial portion (36) in registration with the facial portion of the first end (16). 
Mlaznica za injektiranje prema zahtjevu 4 ili 5, te naročito prema barem jednom od zahtjeva 2 ili 3 ili 6 do 8, naznačena time da kućište ili omotač (30), naročito bočna stjenka, sadrži prednji dio (36) u kontaktu s prednjim dijelom prednjeg kraja (16).
The system according to any preceding claim, wherein the frame comprises an opening (332) for allowing introduction of the deposit into the interior space and a closure member (330) for closing the opening. 
Sustav u skladu sa svakim od prethodnih zahtjeva, naznačen time što okvir sadrži otvor (332) koji omogućava uvođenje umetka u unutrašnji prostor, kao i zatvarač (330), za zatvaranje otvora.
The system according to claim 4 or claim 5, wherein the closure member is located at a forward end of the frame and a retrieval element (14) is located at a rearward end of the frame. 
Sustav, u skladu sa zahtjevom 4 i zahtjevom 5, naznačen time što se zatvarač nalazi na prednjem kraju okvira i što se element za zadržavanje (14) nalazi na zadnjem kraju okvira.
A programmable cylinder lock as set forth in Claim 1, characterized in that said two toothings (7a,7b) of the locking pin (6) or of the key follower (4) which together form a pair are mutually phase displaced of a half of a pitch. 
Programabilna cilindrična brava sukladno Zahtjevu 1, naznačena time što su navedena dva nazubljenja (7a,7b) igle za zaključavanje (6) ili slijeda ključa (4) koji formiraju par međusobno fazno izmještena za polovinu kruga.
A programmable cylinder lock as set forth in Claim 1, characterized in that both members (4,6) of each pair including a locking pin (6) and a key follower (4) have a limited mobility along the direction of the axis of rotor (2). 
Programabilna cilindrična brava sukladno Zahtjevu 1, naznačena time što oba člana (4,6) svakog para uključuju iglu za zaključavanje (6) i slijed ključa (4) te su ograničeno pokretni duž smjera osi rotora (2).
A programmable cylinder lock as set forth in Claim 5, characterized in that both the toothings of the key followers (4) and of the locking pins (6) are provided with said bevel (5a). 
Programabilna cilindrična brava sukladno Zahtjevu 5, naznačena time što su oba nazubljenja sljedova ključa (4) i igala za zaključavanje (6) pružena s navedenim nagibom (5a).
A programmable cylinder lock as set forth in Claim 1, characterized in that said key followers (4) are provided, in the region in which they are slidingly coupled with the change bar (11), with an extension (4a) by means of which they are positively hooked to the change bar (11). 
Programabilna cilindrična brava sukladno Zahtjevu 1, naznačena time što su navedeni sljedovi ključa (4) pruženi u području gdje su klizno upareni sa prečkom za izmjenjivanje (11), s produžetkom pomoću kojeg su spojeni sa prečkom za izmjenjivanje (11).
or Rc" and Rd" together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6alkyl, C1-6haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; 
ili Rc" i Rd" zajedno s atomom dušika na koji su spojeni čine 4-, 5-, 6- ili 7-članu heterocikloalkil skupinu opcionalno supstituiranu s 1, 2, ili 3 supstituenta neovisno izabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 haloalkila, C1-6 haloalkila, arila, arilalkila, heteroarila, heteroarilalkila, cikloalkila i heterocikloalkila;
The compound or salt for use according to claim 1, wherein the compound is a compound of Formula II: or a pharmaceutically acceptable salt thereof. 
Farmaceutski sastav prema zahtjevu 1, pri čemu je spoj spoj Formule II: [image] ili njegova farmaceutski prihvatljiva sol.